https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-09-11 / Int. J. Oncol. 2012 Nov;41(5):1601-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-09-11 / Int. J. Oncol. 2012 Nov;41(5):1601-92012-09-11 00:00:002012-09-11 00:00:00Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-18 / Int. Immunopharmacol. 2011 Dec;11(12):2200-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-18 / Int. Immunopharmacol. 2011 Dec;11(12):2200-72011-10-18 00:00:002019-02-15 08:47:45Improved efficacy of therapeutic vaccination with dendritic cells pulsed with tumor cell lysate against hepatocellular carcinoma by introduction of 2 tandem repeats of microbial HSP70 peptide epitope 407-426 and OK-432
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-09-28 / Clin. Dev. Immunol. 2011;2011:249281
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-09-28 / Clin. Dev. Immunol. 2011;2011:2492812011-09-28 00:00:002020-01-08 10:10:19Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-10-13 / Int. J. Biol. Sci. 2010 Oct;6(7):639-48
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-10-13 / Int. J. Biol. Sci. 2010 Oct;6(7):639-482010-10-13 00:00:002019-02-15 08:47:47Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells loaded with hepatocellular carcinoma -derived RNA or cell lysate
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-22 / Cancer Biol. Ther. 2010 Aug;10(4):368-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-22 / Cancer Biol. Ther. 2010 Aug;10(4):368-752010-08-22 00:00:002020-01-08 10:10:16Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-06-01 / Expert Rev Gastroenterol Hepatol 2010 Jun;4(3):345-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-06-01 / Expert Rev Gastroenterol Hepatol 2010 Jun;4(3):345-532010-06-01 00:00:002019-02-15 09:11:44Immunotherapy of hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-03-30 / Hepatol. Res. 2010 May;40(5):505-13
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-03-30 / Hepatol. Res. 2010 May;40(5):505-132010-03-30 00:00:002019-02-15 09:02:53Dendritic cells fused with allogeneic hepatocellular carcinoma cell line compared with fused autologous tumor cells as hepatocellular carcinoma vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-03-10 / J. Cancer Res. Clin. Oncol. 2010 Nov;136(11):1745-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-03-10 / J. Cancer Res. Clin. Oncol. 2010 Nov;136(11):1745-542010-03-10 00:00:002019-02-15 09:11:45Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-02-28 / Korean J. Physiol. Pharmacol. 2010 Feb;14(1):11-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-02-28 / Korean J. Physiol. Pharmacol. 2010 Feb;14(1):11-42010-02-28 00:00:002019-02-15 08:47:49Dendritic Cells-based Vaccine and Immune Monitoring for Hepatocellular Carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-11-20 / J. Gastroenterol. 2010 Apr;45(4):451-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-11-20 / J. Gastroenterol. 2010 Apr;45(4):451-82009-11-20 00:00:002019-02-15 09:02:54Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma
